{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:53:04Z","timestamp":1793141584926,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/jid.2015.188","type":"journal-article","created":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T10:47:05Z","timestamp":1432118825000},"page":"2402-2409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis"],"prefix":"10.1016","volume":"135","author":[{"given":"Xiang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon W.","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorin K.","family":"Roskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy I.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2015.188_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kem313","article-title":"CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis\u2014a longitudinal study","volume":"47","author":"Antonelli","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1038\/jid.2015.188_bb0015","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4049\/jimmunol.168.3.1139","article-title":"Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling","volume":"168","author":"Atamas","year":"2002","journal-title":"J Immunol"},{"key":"10.1038\/jid.2015.188_bb0020","first-page":"174","article-title":"A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease","volume":"6","author":"Barascuk","year":"2013","journal-title":"Int J Clin Exp Med"},{"key":"10.1038\/jid.2015.188_bb0025","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","article-title":"A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen","volume":"43","author":"Barascuk","year":"2010","journal-title":"Clin Biochem"},{"key":"10.1038\/jid.2015.188_bb0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clinbiochem.2011.01.001","article-title":"Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM\u2014increased serum CIIM in subjects with severe radiographic osteoarthritis","volume":"44","author":"Bay-Jensen","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1038\/jid.2015.188_bb0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"key":"10.1038\/jid.2015.188_bb0040","doi-asserted-by":"crossref","first-page":"e54419","DOI":"10.1371\/journal.pone.0054419","article-title":"The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis","volume":"8","author":"Carmona","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/jid.2015.188_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.imlet.2008.03.016","article-title":"Interferons and scleroderma\u2014a new clue to understanding the pathogenesis of scleroderma?","volume":"118","author":"Coelho","year":"2008","journal-title":"Immunol Lett"},{"key":"10.1038\/jid.2015.188_bb0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/art.1780330310","article-title":"Soluble interleukin-2 receptors in patients with systemic sclerosis. clinical and laboratory correlations","volume":"33","author":"Degiannis","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1038\/jid.2015.188_bb0055","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/ard.2008.096123","article-title":"An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis","volume":"68","author":"Denton","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/jid.2015.188_bb0060","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1172\/JCI112956","article-title":"Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons","volume":"79","author":"Duncan","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1038\/jid.2015.188_bb0065","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/jid.2015.188_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2230.1988.tb00637.x","article-title":"Skin collagen from scleroderma patients before and after cyclosporin A treatment","volume":"13","author":"Frances","year":"1988","journal-title":"Clin Exp Dermatol"},{"key":"10.1038\/jid.2015.188_bb0075","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1186\/1755-1536-6-9","article-title":"Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases","volume":"6","author":"Genovese","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1038\/jid.2015.188_bb0080","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1038\/jid.2015.188_bb0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0190-9622(95)90341-0","article-title":"The use of serologic markers for collagen synthesis and degradation in systemic sclerosis","volume":"32","author":"Heickendorff","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2015.188_bb0090","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/jid.2015.188_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11926-009-0081-6","article-title":"The current state of biomarkers in systemic sclerosis","volume":"12","author":"Hummers","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1038\/jid.2015.188_bb0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/adt.2012.474","article-title":"Extracellular matrix remodeling: The common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure","volume":"11","author":"Karsdal","year":"2013","journal-title":"Assay Drug Dev Technol"},{"key":"10.1038\/jid.2015.188_bb0105","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1002\/art.23994","article-title":"A CD40\u2013CD154 interaction in tissue fibrosis","volume":"58","author":"Kawai","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1038\/jid.2015.188_bb0110","first-page":"514","article-title":"Elevated circulating CD40L concentrations in patients with systemic sclerosis","volume":"31","author":"Komura","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1038\/jid.2015.188_bb0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kramer","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1038\/jid.2015.188_bb0120","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/jid.2015.188_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/ar1976","article-title":"Scar wars: Is TGFbeta the phantom menace in scleroderma?","volume":"8","author":"Leask","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1038\/jid.2015.188_bb0130","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3109\/1354750X.2011.620628","article-title":"A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)","volume":"16","author":"Leeming","year":"2011","journal-title":"Biomarkers"},{"key":"10.1038\/jid.2015.188_bb0135","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1872-034X.2011.00946.x","article-title":"Enzyme-linked immunosorbent serum assay specific for the 7\u2009S domain of collagen type IV (P4NP 7\u2009S): a marker related to the extracellular matrix remodeling during liver fibrogenesis","volume":"42","author":"Leeming","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1038\/jid.2015.188_bb0140","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","article-title":"Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1038\/jid.2015.188_bb0145","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1093\/bioinformatics\/bti551","article-title":"BiNGO: a cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks","volume":"21","author":"Maere","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1038\/jid.2015.188_bb0150","first-page":"165","article-title":"Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis","volume":"23","author":"Nagy","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1038\/jid.2015.188_bb0155","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"key":"10.1038\/jid.2015.188_bb0160","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","article-title":"T cells in systemic sclerosis: a reappraisal","volume":"51","author":"O'Reilly","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1038\/jid.2015.188_bb0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711660307","article-title":"Sequential dermal microvascular and perivascular changes in the development of scleroderma","volume":"166","author":"Prescott","year":"1992","journal-title":"J Pathol"},{"key":"10.1038\/jid.2015.188_bb0170","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps one step ELISA. first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin Chem"},{"key":"10.1038\/jid.2015.188_bb0175","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","article-title":"Interferome v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Rusinova","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/jid.2015.188_bb0180","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","article-title":"A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity","volume":"130","author":"Sargent","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1038\/jid.2015.188_bb0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00002281-199911000-00010","article-title":"Abnormalities of adhesion molecules and chemokines in scleroderma","volume":"11","author":"Sato","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"10.1038\/jid.2015.188_bb0190","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/adt.2009.0258","article-title":"Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: A potential new class of biochemical markers","volume":"8","author":"Skjot-Arkil","year":"2010","journal-title":"Assay Drug Dev Technol"},{"key":"10.1038\/jid.2015.188_bb0195","first-page":"371","article-title":"Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis","volume":"30","author":"Skjot-Arkil","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1038\/jid.2015.188_bb0200","first-page":"625","article-title":"Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis","volume":"22","author":"Solans","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1038\/jid.2015.188_bb0205","first-page":"646","article-title":"Soluble serum interleukin 2 receptors in patients with systemic sclerosis","volume":"23","author":"Steen","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1038\/jid.2015.188_bb0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/art.38194","article-title":"The plasma cell signature in autoimmune disease","volume":"66","author":"Streicher","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1038\/jid.2015.188_bb0215","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2893.2006.00730.x","article-title":"Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin","volume":"13","author":"Trocme","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1038\/jid.2015.188_bb0220","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response","volume":"98","author":"Tusher","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/jid.2015.188_bb0225","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ard.60.6.592","article-title":"European multicentre study to define disease activity criteria for systemic sclerosis. II. identification of disease activity variables and development of preliminary activity indexes","volume":"60","author":"Valentini","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/jid.2015.188_bb0230","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1755-1536-4-22","article-title":"Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis","volume":"4","author":"Veidal","year":"2011","journal-title":"Fibrogen Tissue Rep"},{"key":"10.1038\/jid.2015.188_bb0235","doi-asserted-by":"crossref","first-page":"e24753","DOI":"10.1371\/journal.pone.0024753","article-title":"MMP mediated degradation of type VI collagen is highly associated with liver fibrosis\u2014identification and validation of a novel biochemical marker assay","volume":"6","author":"Veidal","year":"2011","journal-title":"PLoS One"},{"key":"10.1038\/jid.2015.188_bb0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1755-1536-3-5","article-title":"Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats","volume":"3","author":"Veidal","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1038\/jid.2015.188_bb0245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jlb.58.2.209","article-title":"Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation","volume":"58","author":"Yellin","year":"1995","journal-title":"J Leukoc Biol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15418044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15418044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T18:11:02Z","timestamp":1743963062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15418044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0022202X15418044"],"URL":"https:\/\/doi.org\/10.1038\/jid.2015.188","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2015.188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}